Marker Therapeutics, Inc. (MRKR)
All You Need to Know About MARKER THERAPEUTICS (MRKR) Rating Upgrade to Strong Buy
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
MARKER THERAPEUTICS, INC. (MRKR) Now Trades Above Golden Cross: Time to Buy?
After reaching an important support level, MARKER THERAPEUTICS, INC. (MRKR) could be a good stock pick from a technical perspective.
